

# Iraq

Population 2015

36 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.86 (0.018–3.3)	2.4 (0.05–8.9)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0.01–0.02)
Incidence (includes HIV+TB)	16 (14–18)	43 (38–49)
Incidence (HIV+TB only)	0.016 (0.012–0.02)	0.04 (0.03–0.05)
Incidence (MDR/RR-TB)**	1.2 (0.88–1.5)	3.3 (2.4–4.1)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	1 (0.7–1.3)	7.1 (5.8–8.4)	8.1 (6.5–9.8)
Males	0.81 (0.57–1)	6.8 (5.3–8.2)	7.6 (5.9–9.3)
Total	1.8 (1.4–2.2)	14 (13–15)	16 (14–18)

TB case notifications, 2015	
Total cases notified	8 255
Total new and relapse	8 183
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	51%
- % pulmonary	61%
- % bacteriologically confirmed among pulmonary	59%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	52% (46–59)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.06 (0–0.21)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			400 (310–490)
Estimated % of TB cases with MDR/RR-TB	6.1% (4.4–7.8)	24% (16–32)	
% notified tested for rifampicin resistance	1%	25%	279
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 93, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 73, XDR-TB:	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	92%	8 268
Previously treated cases, excluding relapse, registered in 2014	79%	73
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013	58%	84
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2016	
National TB budget (US\$ millions)	26
Funding source: 58% domestic, 42% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse


— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB

Total budget (US\$ millions)



— Unfunded

— Funded internationally

— Funded domestically